Navigation Links
XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Date:9/6/2007

s= "small" HREF="http://studio.financialcontent.com/Engine?Account=prnewswire&PageName=QUOTE&Ticker=XTLB" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur

Chief Executive Officer

Tel: +1-845-267-0707 ext. 225


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
Breaking Biology News(10 mins):Stem cells battle for space 2Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 1Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 2Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 3Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 4Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 5Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 6Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 7Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 8Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 9Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 10Depression Poses Pregnancy Risks 52055 1Depression Poses Pregnancy Risks 52055 2Depression Poses Pregnancy Risks 52055 3The Biggest Loser Confirms Talent6 as a Reality TV Heavyweight 52052 1The Biggest Loser Confirms Talent6 as a Reality TV Heavyweight 52052 2The Biggest Loser Confirms Talent6 as a Reality TV Heavyweight 52052 3